LQDA supply chain intelligence for Liquidia Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Liquidia Corporation (LQDA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| LGM-PHARMA-LLC | LGM-PHARMA-LLC | 92% | we currently rely on a sole supplier, LGM Pharma, LLC ("LGM"), for treprostinil, the active pharmaceutical ingredient of YUTREPIA |
| LONZA-TAMPA-LLC | LONZA-TAMPA-LLC | 92% | we also rely on a sole supplier, Lonza Tampa LLC ("Lonza"), for encapsulation and packaging services for YUTREPIA |
| PLASTIAPE-S-P-A | PLASTIAPE-S-P-A | 92% | we currently rely on a sole supplier, Plastiape S.p.A ("Plastiape"), for RS00 Model DPI, the device used to administer YUTREPIA |
| GSK | GSK plc | 90% | Reciprocal relationship from GSK graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from GSK graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from GSK grap… |
| SANDOZ | SANDOZ | 90% | Supply of Treprostinil Injection is managed directly by our partner Sandoz, who retains the ANDA, manages inventory and records gross revenue on product sales |
| GILD | Gilead Sciences, Inc. | 72% | perational fabrication lines are scaled and capable of producing the necessary materials to support our clinical trials and, if approved, initial commercial demand for YUTREPIA. In August 2021, the F… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from LQDA graph: perational fabrication lines are scaled and capable of producing the necessary materials to support our clinical tria… |
| GOSS | Gossamer Bio, Inc. | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| GOSS | Gossamer Bio, Inc. | 72% | Reciprocal relationship from GOSS graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from GOSS graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability… |
| GSK | GSK plc | 72% | perational fabrication lines are scaled and capable of producing the necessary materials to support our clinical trials and, if approved, initial commercial demand for YUTREPIA. In August 2021, the F… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection… |
| JNJ | Johnson & Johnson | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injecti… |
| NVSEF | Novartis AG | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| ORANY | ORANY | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injecti… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| GOSS | Gossamer Bio, Inc. | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| GOSS | Gossamer Bio, Inc. | 72% | Reciprocal relationship from GOSS graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injectio… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from JNJ grap… |
| JNJ | Johnson & Johnson | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from NVSE… |
| NVSEF | Novartis AG | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| ORANY | ORANY | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from ORAN… |
| CORNER-POST-INC | CORNER-POST-INC | 62% | m with a new discounting program. The IRA permits the Secretary of the HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will c… |
| HEALTHCARE-ROYALTY-PARTNERS | HEALTHCARE-ROYALTY-PARTNERS | 62% | long-term debt. We expect to continue to incur significant expenses as we commercialize YUTREPIA and advance our product candidates through clinical trials and seek regulatory approval of such produc… |
| PAR | PAR Technology Corporation | 62% | Reciprocal relationship from PAR graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from PAR graph: Reciprocal relationship from LQDA graph: is dependent upon our ability and the… |
| PAR-PHARMACEUTICAL-INC | PAR-PHARMACEUTICAL-INC | 62% | is dependent upon our ability and the ability of specialty pharmacies to maintain sufficient inventory of such medical equipment to provide to patients. If manufacturers cease to manufacture or suppo… |
| TEVA | Teva Pharmaceutical Industries Limited | 62% | Reciprocal relationship from TEVA graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from TEVA graph: Reciprocal relationship from LQDA graph: is dependent upon our ability and t… |
| TEVA-PHARMACEUTICAL-INDUSTRIES-LTD | TEVA-PHARMACEUTICAL-INDUSTRIES-LTD | 62% | is dependent upon our ability and the ability of specialty pharmacies to maintain sufficient inventory of such medical equipment to provide to patients. If manufacturers cease to manufacture or suppo… |
| VECTURA-LIMITED | VECTURA-LIMITED | 62% | d stock and common stock, bank borrowings, the issuance of convertible notes, and other long-term debt. Our principal uses of cash have been for working capital requirements and capital expenditures.… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| LQDA-DEBT | Debt stack $19.9M | 90% | Market cache reports total debt of $19.9M. |
| LQDA-DEBT-10789 | Warrants outstanding: 1317000 | 90% | xbrl warrant detail from xbrl 2022-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| LQDA-OWNER-FARALLON-CAPITAL-MANAGEMENT-LLC | FARALLON CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists FARALLON CAPITAL MANAGEMENT LLC as top holder; 253 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| SNNUF | Smith & Nephew plc | 100.00 | 2 | |
| CLGN | CollPlant Biotechnologies Ltd. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| ALC | Alcon Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| BCAX | Bicara Therapeutics Inc. | 100.00 | 2 |